首页 > 最新文献

European Radiology最新文献

英文 中文
Reply to Letter to the Editor: "Ultra-low-dose vs. standard-of-care-dose CT of the chest in patients with post-COVID-19 conditions-a prospective intra-patient multi-reader study". 回复致编辑的信:"COVID-19 后患者的超低剂量与标准护理剂量胸部 CT--一项前瞻性患者内部多读片机研究"。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-04 DOI: 10.1007/s00330-024-11066-y
Christian Wassipaul, Helmut Ringl, Helmut Prosch, Benedikt H Heidinger
{"title":"Reply to Letter to the Editor: \"Ultra-low-dose vs. standard-of-care-dose CT of the chest in patients with post-COVID-19 conditions-a prospective intra-patient multi-reader study\".","authors":"Christian Wassipaul, Helmut Ringl, Helmut Prosch, Benedikt H Heidinger","doi":"10.1007/s00330-024-11066-y","DOIUrl":"10.1007/s00330-024-11066-y","url":null,"abstract":"","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interval breast cancer rates for tomosynthesis vs mammography population screening: a systematic review and meta-analysis of prospective studies. 断层合成与乳腺放射摄影人群筛查的乳腺癌间隔率:前瞻性研究的系统回顾和荟萃分析。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-03 DOI: 10.1007/s00330-024-11085-9
Sol Libesman, Tong Li, M Luke Marinovich, Anna Lene Seidler, Alberto Stefano Tagliafico, Nehmat Houssami

Objectives: We aimed to synthesise evidence from prospective studies of digital breast tomosynthesis (DBT) screening to assess its effectiveness compared to digital mammography (DM). Specifically, we examined whether DBT reduces interval cancer rates (ICRs) in population breast cancer screening.

Materials and methods: We performed a systematic review and meta-analysis of DBT screening studies (identified from January 2013 to March 2024). We included both RCTs and non-randomised prospective studies that used an independent comparison for our primary outcome ICRs. The risk of bias was assessed with QUADAS-2. We compared the ICR, cancer detection rate (CDR), and recall rate of DBT and DM screening using random effects meta-analysis models. Subgroup analyses estimated outcomes by study design. Sensitivity analyses estimated absolute effects from relative effects.

Results: Ten prospective studies (three RCTs, seven non-randomised) were eligible; all had a low risk of bias. There were 205,245 DBT-screened and 306,476 DM-screened participants with follow-up for interval cancer data. The pooled absolute ICR did not significantly differ between DBT and DM: -2.92 per 10,000 screens (95% CI: -6.39 to 0.54); however subsequent subgroup analysis indicated certain study designs may have biased this ICR estimate. Pooled ICR from studies that only sampled groups from the same time and region indicated DBT led to 5.50 less IC per 10,000 screens (95% CI: -9.47 to -1.54). Estimates from subgroup analysis that compared randomised and non-randomised trials did not significantly differ.

Conclusion: This meta-analysis provides suggestive evidence that DBT decreases ICR relative to DM screening; further evidence is needed to reduce uncertainty regarding ICR differences between DBT and DM.

Key points: Question Does DBT have long-term benefits over standard DM? Finding We find suggestive evidence in our primary analysis and stronger evidence in a follow-up analysis that DBT reduces interval cancers. Clinical relevance This meta-analysis provides the first indication that DBT may detect additional cancers that are clinically meaningful, based on suggestive evidence of a reduction in ICR. This finding does not preclude the simultaneous possibility of overdiagnosis.

目的:我们旨在综合数字乳腺断层合成(DBT)筛查前瞻性研究的证据,评估其与数字乳腺X光摄影(DM)相比的有效性。具体来说,我们研究了在人群乳腺癌筛查中,DBT是否降低了间期癌症发生率(ICRs):我们对 DBT 筛查研究(2013 年 1 月至 2024 年 3 月期间确定)进行了系统回顾和荟萃分析。我们纳入了对主要结果ICRs进行独立比较的RCT和非随机前瞻性研究。使用 QUADAS-2 评估了偏倚风险。我们使用随机效应荟萃分析模型比较了DBT和DM筛查的ICR、癌症检出率(CDR)和召回率。亚组分析按研究设计估算了结果。敏感性分析根据相对效应估算绝对效应:十项前瞻性研究(三项 RCT,七项非随机)符合条件;所有研究的偏倚风险都很低。有205245名DBT筛查参与者和306476名DM筛查参与者接受了癌症间期数据的随访。DBT 和 DM 的汇总绝对 ICR 没有显著差异:每 10,000 例筛查中-2.92(95% CI:-6.39 至 0.54);但随后的亚组分析表明,某些研究设计可能会使这一 ICR 估计值出现偏差。从仅对同一时间和同一地区的群体进行采样的研究中汇总的 ICR 表明,DBT 使每 10,000 次筛查中的 IC 减少了 5.50(95% CI:-9.47 至-1.54)。比较随机试验和非随机试验的亚组分析得出的估计值没有显著差异:这项荟萃分析提供了提示性证据,表明相对于 DM 筛查,DBT 可降低 ICR;需要进一步的证据来减少 DBT 和 DM 之间 ICR 差异的不确定性:问题 DBT与标准DM相比是否具有长期益处?结果 我们在主要分析中发现了提示性证据,并在后续分析中发现了更有力的证据,表明 DBT 可减少间期癌症。临床相关性 这项荟萃分析首次表明,基于减少间期癌的提示性证据,DBT 可能会发现更多具有临床意义的癌症。这一发现并不排除同时存在过度诊断的可能性。
{"title":"Interval breast cancer rates for tomosynthesis vs mammography population screening: a systematic review and meta-analysis of prospective studies.","authors":"Sol Libesman, Tong Li, M Luke Marinovich, Anna Lene Seidler, Alberto Stefano Tagliafico, Nehmat Houssami","doi":"10.1007/s00330-024-11085-9","DOIUrl":"https://doi.org/10.1007/s00330-024-11085-9","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to synthesise evidence from prospective studies of digital breast tomosynthesis (DBT) screening to assess its effectiveness compared to digital mammography (DM). Specifically, we examined whether DBT reduces interval cancer rates (ICRs) in population breast cancer screening.</p><p><strong>Materials and methods: </strong>We performed a systematic review and meta-analysis of DBT screening studies (identified from January 2013 to March 2024). We included both RCTs and non-randomised prospective studies that used an independent comparison for our primary outcome ICRs. The risk of bias was assessed with QUADAS-2. We compared the ICR, cancer detection rate (CDR), and recall rate of DBT and DM screening using random effects meta-analysis models. Subgroup analyses estimated outcomes by study design. Sensitivity analyses estimated absolute effects from relative effects.</p><p><strong>Results: </strong>Ten prospective studies (three RCTs, seven non-randomised) were eligible; all had a low risk of bias. There were 205,245 DBT-screened and 306,476 DM-screened participants with follow-up for interval cancer data. The pooled absolute ICR did not significantly differ between DBT and DM: -2.92 per 10,000 screens (95% CI: -6.39 to 0.54); however subsequent subgroup analysis indicated certain study designs may have biased this ICR estimate. Pooled ICR from studies that only sampled groups from the same time and region indicated DBT led to 5.50 less IC per 10,000 screens (95% CI: -9.47 to -1.54). Estimates from subgroup analysis that compared randomised and non-randomised trials did not significantly differ.</p><p><strong>Conclusion: </strong>This meta-analysis provides suggestive evidence that DBT decreases ICR relative to DM screening; further evidence is needed to reduce uncertainty regarding ICR differences between DBT and DM.</p><p><strong>Key points: </strong>Question Does DBT have long-term benefits over standard DM? Finding We find suggestive evidence in our primary analysis and stronger evidence in a follow-up analysis that DBT reduces interval cancers. Clinical relevance This meta-analysis provides the first indication that DBT may detect additional cancers that are clinically meaningful, based on suggestive evidence of a reduction in ICR. This finding does not preclude the simultaneous possibility of overdiagnosis.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: "Ultra-low-dose vs standard-of-care-dose CT of the chest in patients with post-COVID-19 conditions-a prospective intra-patient multi-reader study". 致编辑的信:"COVID-19 后患者胸部超低剂量 CT 与标准剂量 CT 的对比--一项前瞻性患者内部多读片机研究"。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-02 DOI: 10.1007/s00330-024-11065-z
Shritik Devkota, Mandeep Garg, Uma Debi
{"title":"Letter to the Editor: \"Ultra-low-dose vs standard-of-care-dose CT of the chest in patients with post-COVID-19 conditions-a prospective intra-patient multi-reader study\".","authors":"Shritik Devkota, Mandeep Garg, Uma Debi","doi":"10.1007/s00330-024-11065-z","DOIUrl":"10.1007/s00330-024-11065-z","url":null,"abstract":"","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a "pros and cons" debate. 用于乳腺癌患者随访的磁共振对比增强乳腺造影术(CEM):"利弊 "之争。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-01 Epub Date: 2024-03-15 DOI: 10.1007/s00330-024-10684-w
Julia Camps-Herrero, Ruud Pijnappel, Corinne Balleyguier

Women with a personal history of breast cancer (PHBC) are at an increased risk of either a local recurrence or a new primary breast cancer. Thus, surveillance is essential for the detection of recurrent disease at the earliest possible stage, allowing for prompt treatment, and potentially improving overall survival. Nowadays, mammography follow-up is the only surveillance imaging technique recommended by international guidelines. Nevertheless, sensitivity of mammography is lower after breast cancer treatment, particularly during the first 5 years, due to increased density or post-treatment changes. Contrast-enhanced breast imaging techniques, such as MRI or contrast-enhanced mammography (CEM), are very sensitive to detect malignant enhancement, especially in dense breasts. This Special Report will provide arguments in favor of and against breast cancer follow-up with MRI or CEM, in a debate style between experts in Breast Imaging. Finally, the scientific points of pros and cons arguments will be summarized to help objectively decide the best follow-up strategy for women with a personal history of breast cancer. CLINICAL RELEVANCE STATEMENT: A personalized approach to follow-up imaging after conservative breast cancer treatment could optimize patient outcomes, using mammography as a baseline for most patients, and MRI or CEM selectively in patients with higher risks for a recurrence. KEY POINTS: • Women with a personal history of breast cancer are at an increased risk of either a local recurrence or a new primary breast cancer. • Breast cancer survivors may benefit from additional imaging with MRI/CEM, in case of increased risk of a second breast cancer, with dense breasts or a cancer diagnosis before age 50 years. • As survival after local recurrence seems to depend on the initial stage at diagnosis, imaging should be more focused on detecting tumors in the earliest stages.

有乳腺癌(PHBC)个人病史的妇女患局部复发或新的原发性乳腺癌的风险会增加。因此,监测对于尽早发现复发疾病、及时治疗和提高总体生存率至关重要。目前,乳房 X 射线照相术随访是国际指南推荐的唯一监测成像技术。然而,由于密度增加或治疗后的变化,乳腺癌治疗后,尤其是头 5 年,乳腺 X 光造影的灵敏度较低。对比增强乳腺成像技术,如核磁共振成像或对比增强乳腺成像(CEM),对检测恶性增生非常敏感,尤其是在致密乳房中。本特别报告将以乳腺成像专家辩论的形式,提供支持和反对使用 MRI 或 CEM 进行乳腺癌随访的论据。最后,将总结正反方论点的科学依据,以帮助有乳腺癌病史的妇女客观地决定最佳随访策略。临床相关性声明:乳腺癌保守治疗后的个性化随访成像方法可优化患者的预后,对大多数患者使用乳房 X 线照相术作为基线,对复发风险较高的患者有选择性地使用 MRI 或 CEM。要点:- 有乳腺癌病史的妇女患局部复发或新的原发性乳腺癌的风险较高。- 如果乳腺癌幸存者患第二次乳腺癌的风险增加、乳房致密或在 50 岁之前确诊癌症,则可通过磁共振/CEM 进行额外成像。- 由于局部复发后的存活率似乎取决于诊断时的初始阶段,因此影像学检查应更侧重于检测早期阶段的肿瘤。
{"title":"MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a \"pros and cons\" debate.","authors":"Julia Camps-Herrero, Ruud Pijnappel, Corinne Balleyguier","doi":"10.1007/s00330-024-10684-w","DOIUrl":"10.1007/s00330-024-10684-w","url":null,"abstract":"<p><p>Women with a personal history of breast cancer (PHBC) are at an increased risk of either a local recurrence or a new primary breast cancer. Thus, surveillance is essential for the detection of recurrent disease at the earliest possible stage, allowing for prompt treatment, and potentially improving overall survival. Nowadays, mammography follow-up is the only surveillance imaging technique recommended by international guidelines. Nevertheless, sensitivity of mammography is lower after breast cancer treatment, particularly during the first 5 years, due to increased density or post-treatment changes. Contrast-enhanced breast imaging techniques, such as MRI or contrast-enhanced mammography (CEM), are very sensitive to detect malignant enhancement, especially in dense breasts. This Special Report will provide arguments in favor of and against breast cancer follow-up with MRI or CEM, in a debate style between experts in Breast Imaging. Finally, the scientific points of pros and cons arguments will be summarized to help objectively decide the best follow-up strategy for women with a personal history of breast cancer. CLINICAL RELEVANCE STATEMENT: A personalized approach to follow-up imaging after conservative breast cancer treatment could optimize patient outcomes, using mammography as a baseline for most patients, and MRI or CEM selectively in patients with higher risks for a recurrence. KEY POINTS: • Women with a personal history of breast cancer are at an increased risk of either a local recurrence or a new primary breast cancer. • Breast cancer survivors may benefit from additional imaging with MRI/CEM, in case of increased risk of a second breast cancer, with dense breasts or a cancer diagnosis before age 50 years. • As survival after local recurrence seems to depend on the initial stage at diagnosis, imaging should be more focused on detecting tumors in the earliest stages.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthetic MRI and amide proton transfer-weighted MRI for differentiating between benign and malignant sinonasal lesions. 合成磁共振成像和酰胺质子传递加权磁共振成像用于区分鼻窦良性和恶性病变。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-01 Epub Date: 2024-03-16 DOI: 10.1007/s00330-024-10696-6
Ying Xiang, Qiujuan Zhang, Xin Chen, Honghong Sun, Xiaohui Li, Xiaocheng Wei, Jinman Zhong, Bo Gao, Wei Huang, Wenbin Liang, Haiqiao Sun, Quanxin Yang, Xiaoyong Ren

Objectives: To explore the value of the synthetic MRI (SyMRI), combined with amide proton transfer-weighted (APTw) MRI for quantitative and morphologic assessment of sinonasal lesions, which could provide relative scale for the quantitative assessment of tissue properties.

Methods: A total of 80 patients (31 malignant and 49 benign) with sinonasal lesions, who underwent the SyMRI and APTw examination, were retrospectively analyzed. Quantitative parameters (T1, T2, proton density (PD)) and APT % were obtained through outlining the region of interest (ROI) and comparing the two groups utilizing independent Student t test or a Wilcoxon test. Receiver operating characteristic curve (ROC), Delong test, and logistic regression analysis were performed to assess the diagnostic efficiency of one-parameter and multiparametric models.

Results: SyMRI-derived mean T1, T2, and PD were significantly higher and APT % was relatively lower in benign compared to malignant sinonasal lesions (p < 0.05). The ROC analysis showed that the AUCs of the SyMRI-derived quantitative (T1, T2, PD) values and APT % ranged from 0.677 to 0.781 for differential diagnosis between benign and malignant sinonasal lesions. The T2 values showed the best diagnostic performance among all single parameters for differentiating these two masses. The AUCs of combined SyMRI-derived multiple parameters with APT % (AUC = 0.866) were the highest than that of any single parameter, which was significantly improved (p < 0.05).

Conclusion: The combination of SyMRI and APTw imaging has the potential to reflect intrinsic tissue characteristics useful for differentiating benign from malignant sinonasal lesions.

Clinical relevance statement: Combining synthetic MRI with amide proton transfer-weighted imaging could function as a quantitative and contrast-free approach, significantly enhancing the differentiation of benign and malignant sinonasal lesions and overcoming the limitations associated with the superficial nature of endoscopic nasal sampling.

Key points: • Synthetic MRI and amide proton transfer-weighted MRI could differentiate benign from malignant sinonasal lesions based on quantitative parameters. • The diagnostic efficiency could be significantly improved through synthetic MRI + amide proton transfer-weighted imaging. • The combination of synthetic MRI and amide proton transfer-weighted MRI is a noninvasive method to evaluate sinonasal lesions.

研究目的探讨合成磁共振成像(SyMRI)结合酰胺质子转移加权磁共振成像(APTw)对鼻窦病变进行定量和形态学评估的价值,这可以为组织特性的定量评估提供相对尺度:方法:对接受 SyMRI 和 APTw 检查的 80 例鼻窦病变患者(31 例恶性,49 例良性)进行回顾性分析。通过勾画感兴趣区(ROI)获得定量参数(T1、T2、质子密度(PD))和 APT%,并利用独立的学生 t 检验或 Wilcoxon 检验比较两组患者。为了评估单参数模型和多参数模型的诊断效率,还进行了接收者操作特征曲线(ROC)、Delong 检验和逻辑回归分析:结果:与恶性鼻窦病变相比,良性鼻窦病变的 SyMRI 导出平均 T1、T2 和 PD 明显更高,APT % 则相对更低(p 结论:SyMRI 和 APT 的组合可用于诊断恶性鼻窦病变:结合 SyMRI 和 APTw 成像有可能反映出组织的内在特征,有助于区分良性和恶性鼻窦病变:将合成磁共振成像与酰胺质子转移加权成像相结合,可作为一种定量和无对比度的方法,显著提高鼻窦良性和恶性病变的鉴别能力,并克服鼻内窥镜取样浅表性带来的局限性:- 要点:合成磁共振成像和酰胺质子传递加权磁共振成像可根据定量参数区分鼻窦病变的良恶性。- 合成磁共振成像+酰胺质子转移加权成像可显著提高诊断效率。- 合成磁共振成像和酰胺质子转移加权磁共振成像相结合是一种评估鼻窦病变的无创方法。
{"title":"Synthetic MRI and amide proton transfer-weighted MRI for differentiating between benign and malignant sinonasal lesions.","authors":"Ying Xiang, Qiujuan Zhang, Xin Chen, Honghong Sun, Xiaohui Li, Xiaocheng Wei, Jinman Zhong, Bo Gao, Wei Huang, Wenbin Liang, Haiqiao Sun, Quanxin Yang, Xiaoyong Ren","doi":"10.1007/s00330-024-10696-6","DOIUrl":"10.1007/s00330-024-10696-6","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the value of the synthetic MRI (SyMRI), combined with amide proton transfer-weighted (APTw) MRI for quantitative and morphologic assessment of sinonasal lesions, which could provide relative scale for the quantitative assessment of tissue properties.</p><p><strong>Methods: </strong>A total of 80 patients (31 malignant and 49 benign) with sinonasal lesions, who underwent the SyMRI and APTw examination, were retrospectively analyzed. Quantitative parameters (T1, T2, proton density (PD)) and APT % were obtained through outlining the region of interest (ROI) and comparing the two groups utilizing independent Student t test or a Wilcoxon test. Receiver operating characteristic curve (ROC), Delong test, and logistic regression analysis were performed to assess the diagnostic efficiency of one-parameter and multiparametric models.</p><p><strong>Results: </strong>SyMRI-derived mean T1, T2, and PD were significantly higher and APT % was relatively lower in benign compared to malignant sinonasal lesions (p < 0.05). The ROC analysis showed that the AUCs of the SyMRI-derived quantitative (T1, T2, PD) values and APT % ranged from 0.677 to 0.781 for differential diagnosis between benign and malignant sinonasal lesions. The T2 values showed the best diagnostic performance among all single parameters for differentiating these two masses. The AUCs of combined SyMRI-derived multiple parameters with APT % (AUC = 0.866) were the highest than that of any single parameter, which was significantly improved (p < 0.05).</p><p><strong>Conclusion: </strong>The combination of SyMRI and APTw imaging has the potential to reflect intrinsic tissue characteristics useful for differentiating benign from malignant sinonasal lesions.</p><p><strong>Clinical relevance statement: </strong>Combining synthetic MRI with amide proton transfer-weighted imaging could function as a quantitative and contrast-free approach, significantly enhancing the differentiation of benign and malignant sinonasal lesions and overcoming the limitations associated with the superficial nature of endoscopic nasal sampling.</p><p><strong>Key points: </strong>• Synthetic MRI and amide proton transfer-weighted MRI could differentiate benign from malignant sinonasal lesions based on quantitative parameters. • The diagnostic efficiency could be significantly improved through synthetic MRI + amide proton transfer-weighted imaging. • The combination of synthetic MRI and amide proton transfer-weighted MRI is a noninvasive method to evaluate sinonasal lesions.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140140173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spontaneous perforation of the common bile duct: an uncommon complication of primary sclerosing cholangitis. 胆总管自发性穿孔:原发性硬化性胆管炎的罕见并发症。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-01 Epub Date: 2024-03-21 DOI: 10.1007/s00330-024-10704-9
Lucas Dargent, Sara Lemoinne, Karine Louvion, Pauline Iorio, Christophe Corpechot, Sanaâ El Mouhadi, Quentin Vanderbecq, Olivier Chazouillères, Lionel Arrivé

Objectives: To describe the MR features and prognosis of patients with an uncommon complication of primary sclerosing cholangitis (PSC) characterized by a spontaneous perforation of the common bile duct (CBD) resulting in a peri-biliary collection and a pseudo-cystic appearance of the CBD.

Methods: A single-center cohort of 263 patients with PSC who had at least two MRIs between 2003 and 2022 and a minimum follow-up of 1 year was retrospectively analyzed. MRI data (characteristics of CBD perforation and MR features of PSC) and clinical data were assessed. Analysis of survival without liver transplantation according to type of PSC (classical or CBD spontaneous perforation) was performed according to the Kaplan-Meier method and the curves were compared using the Log-Rank test.

Results: A total of nine (3.4%) PSC patients (5 males) had perforation of the CBD with a median age at diagnosis of 18 years compared to 33 years for the control group (p = 0.019). The peri-biliary collections were variable in appearance (fusiform or pedunculated), with a diameter ranging from 5 to 54 mm. All nine patients showed intra- and extra-hepatic bile duct involvement, dysmorphia, and high ANALI scores. The clinical course was characterized by numerous complications in most patients, and five patients (56%) underwent liver transplantation at a median time of 5 years from diagnosis, compared to 40 patients (16%) in the control group (p = 0.02).

Conclusion: The spontaneous perforation of the common bile duct is an uncommon complication of primary sclerosing cholangitis that affects young patients and is associated with a poor prognosis.

Clinical relevance statement: This uncommon complication of primary sclerosing cholangitis with perforation of the common bile duct resulting in a peri-biliary collection and a pseudo-cystic appearance of the common bile duct is characterized by a poor prognosis in younger patients.

Key points: • Among 263 patients with primary sclerosing cholangitis (PSC), nine patients (3.6%) had an uncommon complication characterized on MRI by perforation of the common bile duct (CBD). • This perforation of the CBD was responsible in all nine cases for the formation of a peri-biliary collection, giving a pseudo-cystic appearance to the CBD. • The spontaneous perforation of the common bile duct is an uncommon complication of primary sclerosing cholangitis that affects young patients with a poor prognosis.

目的描述原发性硬化性胆管炎(PSC)一种不常见并发症患者的磁共振特征和预后,该并发症的特征是总胆管(CBD)自发性穿孔导致胆管周围集结和CBD出现假性囊肿:方法:对2003年至2022年期间至少进行过两次磁共振成像且随访至少1年的263例PSC患者进行了单中心队列回顾性分析。评估了磁共振成像数据(CBD穿孔特征和PSC的磁共振特征)和临床数据。根据PSC类型(典型或CBD自发性穿孔),采用Kaplan-Meier法分析未接受肝移植的存活率,并使用Log-Rank检验比较曲线:共有9名(3.4%)PSC患者(5名男性)出现CBD穿孔,诊断时的中位年龄为18岁,而对照组为33岁(P = 0.019)。胆道周围积液的外观各不相同(纺锤形或有蒂的积液),直径从 5 毫米到 54 毫米不等。所有九名患者均表现为肝内外胆管受累、畸形和高 ANALI 评分。大多数患者的临床病程以并发症多为特征,5 名患者(56%)在确诊后的中位时间为 5 年时接受了肝移植,而对照组有 40 名患者(16%)接受了肝移植(P = 0.02):结论:胆总管自发性穿孔是原发性硬化性胆管炎的一种不常见并发症,多发于年轻患者,预后较差:原发性硬化性胆管炎不常见的并发症是胆总管穿孔,导致胆汁周围集结和胆总管假性囊肿,年轻患者的预后较差:- 在263名原发性硬化性胆管炎(PSC)患者中,有9名患者(3.6%)出现了一种不常见的并发症,即磁共振成像显示总胆管(CBD)穿孔。- 这九例患者的胆总管穿孔均导致胆管周围集结,使胆总管呈现假性囊性外观。- 胆总管自发性穿孔是原发性硬化性胆管炎的一种不常见并发症,多发于预后不良的年轻患者。
{"title":"Spontaneous perforation of the common bile duct: an uncommon complication of primary sclerosing cholangitis.","authors":"Lucas Dargent, Sara Lemoinne, Karine Louvion, Pauline Iorio, Christophe Corpechot, Sanaâ El Mouhadi, Quentin Vanderbecq, Olivier Chazouillères, Lionel Arrivé","doi":"10.1007/s00330-024-10704-9","DOIUrl":"10.1007/s00330-024-10704-9","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the MR features and prognosis of patients with an uncommon complication of primary sclerosing cholangitis (PSC) characterized by a spontaneous perforation of the common bile duct (CBD) resulting in a peri-biliary collection and a pseudo-cystic appearance of the CBD.</p><p><strong>Methods: </strong>A single-center cohort of 263 patients with PSC who had at least two MRIs between 2003 and 2022 and a minimum follow-up of 1 year was retrospectively analyzed. MRI data (characteristics of CBD perforation and MR features of PSC) and clinical data were assessed. Analysis of survival without liver transplantation according to type of PSC (classical or CBD spontaneous perforation) was performed according to the Kaplan-Meier method and the curves were compared using the Log-Rank test.</p><p><strong>Results: </strong>A total of nine (3.4%) PSC patients (5 males) had perforation of the CBD with a median age at diagnosis of 18 years compared to 33 years for the control group (p = 0.019). The peri-biliary collections were variable in appearance (fusiform or pedunculated), with a diameter ranging from 5 to 54 mm. All nine patients showed intra- and extra-hepatic bile duct involvement, dysmorphia, and high ANALI scores. The clinical course was characterized by numerous complications in most patients, and five patients (56%) underwent liver transplantation at a median time of 5 years from diagnosis, compared to 40 patients (16%) in the control group (p = 0.02).</p><p><strong>Conclusion: </strong>The spontaneous perforation of the common bile duct is an uncommon complication of primary sclerosing cholangitis that affects young patients and is associated with a poor prognosis.</p><p><strong>Clinical relevance statement: </strong>This uncommon complication of primary sclerosing cholangitis with perforation of the common bile duct resulting in a peri-biliary collection and a pseudo-cystic appearance of the common bile duct is characterized by a poor prognosis in younger patients.</p><p><strong>Key points: </strong>• Among 263 patients with primary sclerosing cholangitis (PSC), nine patients (3.6%) had an uncommon complication characterized on MRI by perforation of the common bile duct (CBD). • This perforation of the CBD was responsible in all nine cases for the formation of a peri-biliary collection, giving a pseudo-cystic appearance to the CBD. • The spontaneous perforation of the common bile duct is an uncommon complication of primary sclerosing cholangitis that affects young patients with a poor prognosis.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of smoking on the diagnostic results and complication rates of percutaneous transthoracic needle biopsy. 吸烟对经皮穿刺活检的诊断结果和并发症发生率的影响。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-01 Epub Date: 2024-03-25 DOI: 10.1007/s00330-024-10705-8
Woo Hyeon Lim, Jong Hyuk Lee, Hyungin Park, Chang Min Park, Soon Ho Yoon

Objective: To investigate the association of smoking with the outcomes of percutaneous transthoracic needle biopsy (PTNB).

Methods: In total, 4668 PTNBs for pulmonary lesions were retrospectively identified. The associations of smoking status (never, former, current smokers) and smoking intensity (≤ 20, 21-40, > 40 pack-years) with diagnostic results (malignancy, non-diagnostic pathologies, and false-negative results in non-diagnostic pathologies) and complications (pneumothorax and hemoptysis) were assessed using multivariable logistic regression analysis.

Results: Among the 4668 PTNBs (median age of the patients, 66 years [interquartile range, 58-74]; 2715 men), malignancies, non-diagnostic pathologies, and specific benign pathologies were identified in 3054 (65.4%), 1282 (27.5%), and 332 PTNBs (7.1%), respectively. False-negative results for malignancy occurred in 20.5% (236/1153) of non-diagnostic pathologies with decidable reference standards. Current smoking was associated with malignancy (adjusted odds ratio [OR], 1.31; 95% confidence interval [CI]: 1.02-1.69; p = 0.03) and false-negative results (OR, 2.64; 95% CI: 1.32-5.28; p = 0.006), while heavy smoking (> 40 pack-years) was associated with non-diagnostic pathologies (OR, 1.69; 95% CI: 1.19-2.40; p = 0.003) and false-negative results (OR, 2.12; 95% CI: 1.17-3.92; p = 0.02). Pneumothorax and hemoptysis occurred in 21.8% (1018/4668) and 10.6% (495/4668) of PTNBs, respectively. Heavy smoking was associated with pneumothorax (OR, 1.33; 95% CI: 1.01-1.74; p = 0.04), while heavy smoking (OR, 0.64; 95% CI: 0.40-0.99; p = 0.048) and current smoking (OR, 0.64; 95% CI: 0.42-0.96; p = 0.04) were inversely associated with hemoptysis.

Conclusion: Smoking history was associated with the outcomes of PTNBs. Current and heavy smoking increased false-negative results and changed the complication rates of PTNBs.

Clinical relevance statement: Smoking status and intensity were independently associated with the outcomes of PTNBs. Non-diagnostic pathologies should be interpreted cautiously in current or heavy smokers. A patient's smoking history should be ascertained before PTNB to predict and manage complications.

Key points: • Smoking status and intensity might independently contribute to the diagnostic results and complications of PTNBs. • Current and heavy smoking (> 40 pack-years) were independently associated with the outcomes of PTNBs. • Operators need to recognize the association between smoking history and the outcomes of PTNBs.

目的:研究吸烟与经皮穿刺活检(PTNB)结果的关系:研究吸烟与经皮穿刺活检(PTNB)结果的关系:方法:对4668例肺部病变经皮穿刺活检进行了回顾性鉴定。采用多变量逻辑回归分析评估了吸烟状态(从不吸烟、曾经吸烟、目前吸烟)和吸烟强度(≤20包年、21-40包年、>40包年)与诊断结果(恶性肿瘤、非诊断性病变、非诊断性病变的假阴性结果)和并发症(气胸和咯血)之间的关系:在 4668 例 PTNB 中(患者的中位年龄为 66 岁[四分位间范围为 58-74];男性 2715 例),分别有 3054 例(65.4%)、1282 例(27.5%)和 332 例(7.1%) PTNB 发现了恶性肿瘤、非诊断性病变和特定良性病变。在有明确参考标准的非诊断性病理中,20.5%(236/1153)的病理出现了恶性肿瘤假阴性结果。目前吸烟与恶性肿瘤有关(调整后的几率比[OR],1.31;95% 置信区间[CI]:大量吸烟(大于 40 包年)与非诊断性病变(OR,1.69;95% CI:1.19-2.40;p = 0.003)和假阴性结果(OR,2.12;95% CI:1.17-3.92;p = 0.02)有关。在 PTNB 中,分别有 21.8%(1018/4668)和 10.6%(495/4668)的患者出现气胸和咯血。大量吸烟与气胸相关(OR,1.33;95% CI:1.01-1.74;p = 0.04),而大量吸烟(OR,0.64;95% CI:0.40-0.99;p = 0.048)和当前吸烟(OR,0.64;95% CI:0.42-0.96;p = 0.04)与咯血成反比:结论:吸烟史与 PTNB 的结果有关。结论:吸烟史与 PTNB 的结果有关,目前吸烟和大量吸烟会增加假阴性结果,并改变 PTNB 的并发症发生率:临床相关性声明:吸烟状况和强度与 PTNB 的结果独立相关。对于正在吸烟或大量吸烟的患者,应谨慎解释非诊断性病变。在进行 PTNB 之前应确定患者的吸烟史,以预测和处理并发症:- 要点:吸烟状态和强度可能会对 PTNB 的诊断结果和并发症产生独立影响。- 目前吸烟和大量吸烟(> 40 包年)与 PTNB 的结果密切相关。- 操作者需要认识到吸烟史与 PTNBs 结果之间的关联。
{"title":"Effect of smoking on the diagnostic results and complication rates of percutaneous transthoracic needle biopsy.","authors":"Woo Hyeon Lim, Jong Hyuk Lee, Hyungin Park, Chang Min Park, Soon Ho Yoon","doi":"10.1007/s00330-024-10705-8","DOIUrl":"10.1007/s00330-024-10705-8","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association of smoking with the outcomes of percutaneous transthoracic needle biopsy (PTNB).</p><p><strong>Methods: </strong>In total, 4668 PTNBs for pulmonary lesions were retrospectively identified. The associations of smoking status (never, former, current smokers) and smoking intensity (≤ 20, 21-40, > 40 pack-years) with diagnostic results (malignancy, non-diagnostic pathologies, and false-negative results in non-diagnostic pathologies) and complications (pneumothorax and hemoptysis) were assessed using multivariable logistic regression analysis.</p><p><strong>Results: </strong>Among the 4668 PTNBs (median age of the patients, 66 years [interquartile range, 58-74]; 2715 men), malignancies, non-diagnostic pathologies, and specific benign pathologies were identified in 3054 (65.4%), 1282 (27.5%), and 332 PTNBs (7.1%), respectively. False-negative results for malignancy occurred in 20.5% (236/1153) of non-diagnostic pathologies with decidable reference standards. Current smoking was associated with malignancy (adjusted odds ratio [OR], 1.31; 95% confidence interval [CI]: 1.02-1.69; p = 0.03) and false-negative results (OR, 2.64; 95% CI: 1.32-5.28; p = 0.006), while heavy smoking (> 40 pack-years) was associated with non-diagnostic pathologies (OR, 1.69; 95% CI: 1.19-2.40; p = 0.003) and false-negative results (OR, 2.12; 95% CI: 1.17-3.92; p = 0.02). Pneumothorax and hemoptysis occurred in 21.8% (1018/4668) and 10.6% (495/4668) of PTNBs, respectively. Heavy smoking was associated with pneumothorax (OR, 1.33; 95% CI: 1.01-1.74; p = 0.04), while heavy smoking (OR, 0.64; 95% CI: 0.40-0.99; p = 0.048) and current smoking (OR, 0.64; 95% CI: 0.42-0.96; p = 0.04) were inversely associated with hemoptysis.</p><p><strong>Conclusion: </strong>Smoking history was associated with the outcomes of PTNBs. Current and heavy smoking increased false-negative results and changed the complication rates of PTNBs.</p><p><strong>Clinical relevance statement: </strong>Smoking status and intensity were independently associated with the outcomes of PTNBs. Non-diagnostic pathologies should be interpreted cautiously in current or heavy smokers. A patient's smoking history should be ascertained before PTNB to predict and manage complications.</p><p><strong>Key points: </strong>• Smoking status and intensity might independently contribute to the diagnostic results and complications of PTNBs. • Current and heavy smoking (> 40 pack-years) were independently associated with the outcomes of PTNBs. • Operators need to recognize the association between smoking history and the outcomes of PTNBs.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Active surveillance of prostate cancer: MRI and beyond. 前列腺癌的主动监测:磁共振成像及其他
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-01 Epub Date: 2024-03-28 DOI: 10.1007/s00330-024-10717-4
Rossano Girometti, Francesco Giganti
{"title":"Active surveillance of prostate cancer: MRI and beyond.","authors":"Rossano Girometti, Francesco Giganti","doi":"10.1007/s00330-024-10717-4","DOIUrl":"10.1007/s00330-024-10717-4","url":null,"abstract":"","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do we need to monitor B3 lesions? 我们需要监测 B3 病变吗?
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-01 DOI: 10.1007/s00330-024-11092-w
Maria Adele Marino, Antonio Portaluri, Carmelo Sofia
{"title":"Do we need to monitor B3 lesions?","authors":"Maria Adele Marino, Antonio Portaluri, Carmelo Sofia","doi":"10.1007/s00330-024-11092-w","DOIUrl":"https://doi.org/10.1007/s00330-024-11092-w","url":null,"abstract":"","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. 用不可逆电穿孔技术使最初无法切除的局部晚期胰腺癌接受手术治疗:IRECAP II 期研究。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-10-01 Epub Date: 2024-03-18 DOI: 10.1007/s00330-024-10613-x
Jean-Pierre Tasu, Guillaume Herpe, Jérôme Damion, Jean-Pierre Richer, Bertrand Debeane, Mathilde Vionnet, Laetitia Rouleau, Michel Carretier, Aurélie Ferru, Pierre Ingrand, David Tougeron

Objectives: The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).

Materials and methods: IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).

Results: Six men and 11 women were included (median age 61 years, range 37-77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (n = 6/17). Median overall survival was 31 months (95% CI; 4-undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4-25) for the 11 patients without resection or R2 resection (logrank p = 0.044).

Conclusion: After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.

Clinical relevance statement: After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.

Key points: • In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3-4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4-undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4-25) for the patients without resection or R2 resection (logrank p = 0.044).

研究目的IRECAP 研究旨在评估局部晚期胰腺癌患者(LAPC)在接受不可逆电穿孔术(IRE)后接受 R0 或 R1 手术的比例:IRECAP研究是一项在clinicaltrials.gov(NCT03105921)上注册的II期、单中心、开放标签、前瞻性、非随机试验。LAPC患者首先接受为期3个月的新辅助化疗,以避免纳入化疗后可切除的LAPC患者或疾病进展迅速的患者。如果病情稳定,则在 CT 引导下经皮进行 IRE。手术计划在IRE后28至90天之间进行。对肿瘤标本进行研究,以评估切除边缘(R0/R1/R2):结果:共纳入 6 名男性和 11 名女性(中位年龄 61 岁,年龄范围 37-77 岁)。未发现与 IRE 相关的死亡病例。10名患者(58%,10/17)发生了25起与IRE相关的严重不良事件。四名患者在 IRE 和手术之间病情恶化,被排除在手术之外。13 名患者最终接受了手术,其中 6 名患者因胰腺切除而暂缓手术,3 名患者因弥漫性腹膜癌而暂缓手术,2 名患者因大量血管嵌顿而暂缓手术,1 名患者因术前未确诊的肝细胞癌而暂缓手术。R1-R0率为35%(n=6/17)。6例R0/R1切除患者的中位总生存期为31个月(95% CI;4-未定义),11例未切除或R2切除患者的中位总生存期为21个月(95% CI;4-25)(logrank p = 0.044):结论:新辅助化疗后,IRE可使35%的LAPC患者获得R0或R1切除,这似乎与较高的OS有关:诱导化疗后,稳定的局部晚期胰腺癌可通过不可逆电穿孔治疗,这可使35%的手术切除率达到R0或R1,从而显著提高总生存率:- 对于无法切除的局部晚期胰腺癌(LAPC),经皮不可逆电穿孔疗法(pIRE)是可行的(手术成功率为100%),但3-4级不良反应发生率为58%。- 对于无法切除的 LAPC 患者,pIRE 可使 35% 的患者接受 R0-R1 手术切除。- IRE后,R0/R1切除患者的中位总生存期为31个月(95% CI;4-未定义),未切除或R2切除患者的中位总生存期为21个月(95% CI;4-25)(logrank p = 0.044)。
{"title":"Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study.","authors":"Jean-Pierre Tasu, Guillaume Herpe, Jérôme Damion, Jean-Pierre Richer, Bertrand Debeane, Mathilde Vionnet, Laetitia Rouleau, Michel Carretier, Aurélie Ferru, Pierre Ingrand, David Tougeron","doi":"10.1007/s00330-024-10613-x","DOIUrl":"10.1007/s00330-024-10613-x","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).</p><p><strong>Materials and methods: </strong>IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).</p><p><strong>Results: </strong>Six men and 11 women were included (median age 61 years, range 37-77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (n = 6/17). Median overall survival was 31 months (95% CI; 4-undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4-25) for the 11 patients without resection or R2 resection (logrank p = 0.044).</p><p><strong>Conclusion: </strong>After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.</p><p><strong>Clinical relevance statement: </strong>After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.</p><p><strong>Key points: </strong>• In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3-4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4-undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4-25) for the patients without resection or R2 resection (logrank p = 0.044).</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140142985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Radiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1